MarketCapExport financials
AbCellera Biologics (ABCL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
AbCellera Biologics Financial Ratios 2025-2011 | ABCL
Brief overview of AbCellera Biologics's multiples and efficiency
Current figures are compared with the company's own five-year history for 2021–2025.
The valuation comparison uses P/E 16.02x (median 16.02x), EV/EBITDA 10.07x (median 10.07x), P/S 12.8x (median 12.8x). Current valuation broadly matches recent historical reference points; the difference from five-year medians is 0%.
Current earnings relative to valuation equal about 6.2% on the 1/P/E measure. This is a valuation reference, not an expected payout.
Returns on assets and capital are represented by ROE -15.1%, ROA -10.8%, ROCE -16.8%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
PEG of 0.17x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
The cash conversion cycle decreased 29 days to 173.4 days, supporting working-capital efficiency.
Overall assessment
AbCellera Biologics's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios AbCellera Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-6.6 | -5.3 | -10.4 | 16.0 | 15.7 | 50.5 | - | - | - | - | - | - | - | - | - |
P/S |
12.8 | 29.8 | 40.2 | 5.2 | 6.4 | 25.7 | - | - | - | - | - | - | - | - | - |
EPS |
-0.5 | -0.6 | -0.5 | 0.6 | 0.6 | 0.5 | -0.0 | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
1.22 B | 1.01 B | 1.73 B | 2.46 B | 2.19 B | 5.58 B | 13.2 M | 9.88 M | - | - | - | - | - | - | - |
EBITDA per Share |
-0.67 | -1.03 | -0.74 | 0.86 | 0.79 | 0.99 | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
-6.2 | -3.3 | -8.1 | 10.1 | 9.2 | 50.3 | - | - | - | - | - | - | - | - | - |
PEG |
0.17 | - | - | - | - | 0.01 | - | - | - | - | - | - | - | - | - |
P/B |
1.0 | 0.8 | 1.3 | 2.1 | 2.3 | 7.2 | - | - | - | - | - | - | - | - | - |
P/CF |
-7.3 | -7.9 | -34.8 | 9.2 | 9.8 | 264.6 | - | - | - | - | - | - | - | - | - |
ROE % |
-15.14 | -15.42 | -12.70 | 12.85 | 14.96 | 14.32 | - | - | - | - | - | - | - | - | - |
ROA % |
-10.79 | -11.97 | -9.84 | 10.29 | 11.64 | 11.83 | - | - | - | - | - | - | - | - | - |
ROCE % |
-16.80 | -24.52 | -17.33 | 15.22 | 17.06 | 17.30 | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.5 | 4.5 | 4.4 | 5.0 | 4.5 | 5.7 | - | - | - | - | - | - | - | - | - |
DSO |
173.4 | 202.4 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
173.4 | 202.4 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
173.4 | 202.4 | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios AbCellera Biologics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.18 | -0.14 | -0.19 | -0.12 | -0.15 | - | -0.17 | -0.13 | -0.14 | - | -0.1 | -0.11 | -0.14 | - | 0.09 | -0.02 | 0.59 | - | -0.08 | -0.01 | 0.43 | - | -0.02 | 0.03 | -0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.18 | -0.17 | -0.24 | -0.15 | -0.19 | - | -0.19 | -0.19 | -0.17 | - | -0.18 | -0.17 | -0.21 | - | 0.15 | -0.01 | 0.81 | - | -0.09 | -0.01 | 0.6 | - | -0.01 | - | -0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-20.16 | -18.43 | -18.57 | -15.97 | -16.12 | -11.66 | -14.08 | -11.89 | -11.89 | -8.29 | -6.16 | -4.30 | 12.21 | 15.53 | 13.29 | 10.92 | 23.73 | 9.76 | 9.44 | 12.49 | 12.48 | 0.23 | -0.32 | 0.81 | -0.25 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-14.23 | -13.39 | -13.75 | -12.15 | -12.45 | -9.06 | -10.95 | -9.27 | -9.33 | -6.56 | -4.84 | -3.37 | 9.20 | 11.88 | 10.05 | 8.14 | 18.95 | 8.36 | 8.09 | 10.58 | 10.58 | 0.19 | -0.27 | 0.67 | -0.21 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-19.21 | -19.14 | -21.71 | -22.75 | -23.08 | -18.14 | -22.05 | -18.54 | -16.19 | -12.15 | -9.54 | -6.23 | 13.70 | 18.31 | 15.81 | 12.55 | 28.36 | 12.05 | 11.85 | 14.26 | 14.67 | -0.53 | -0.20 | -0.09 | -0.24 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.2 | 3.5 | 3.5 | 3.5 | 4.2 | 4.5 | 4.4 | 4.7 | 4.4 | 4.4 | 4.6 | 4.5 | 5.2 | 5.0 | 5.1 | 4.2 | 4.1 | 4.5 | 5.3 | 6.2 | 6.6 | 5.8 | 5.8 | 5.8 | 5.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
874.0 | 605.8 | 719.7 | 356.8 | 1029.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.2 | 43.2 | 5.5 | - | - | 3.7 | 8.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 719.7 | 356.8 | 1029.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.2 | 43.2 | 5.5 | - | - | 3.7 | 8.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 719.7 | 356.8 | 1029.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.2 | 43.2 | 5.5 | - | - | 3.7 | 8.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company AbCellera Biologics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
- | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
$ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alector
ALEC
|
$ 2.19 | 2.1 % | $ 226 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.08 | 0.96 % | $ 50.2 M | USA |
 |
Alkermes plc
ALKS
|
$ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.79 | 0.28 % | $ 395 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 248.37 | 0.14 % | $ 32.5 B | USA |
 |
Altimmune
ALT
|
$ 3.31 | 1.22 % | $ 292 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.93 | 0.52 % | $ 104 M | USA |
 |
Amgen
AMGN
|
$ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
$ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
$ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.76 | 2.03 % | $ 4.97 M | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.87 | 2.75 % | $ 590 K | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
$ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Artelo Biosciences
ARTL
|
$ 5.15 | 1.1 % | $ 974 K | USA |
 |
Arvinas
ARVN
|
$ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 28.86 | 0.64 % | $ 324 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.25 | 6.87 % | $ 39 M | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
$ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | 1.26 % | $ 2.19 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
$ 5.34 | 0.47 % | $ 435 M | USA |
 |
Axon Enterprise
AXON
|
$ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
$ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
$ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
$ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
$ 2.03 | 2.52 % | $ 115 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 24.35 | 1.5 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
$ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.48 | 0.2 % | $ 6.11 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
$ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
$ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.11 | 0.08 % | $ 498 M | USA |
 |
Burford Capital Limited
BUR
|
$ 4.35 | 1.13 % | $ 953 M | Britain |